What Is HGH191AA?
HGH191AA refers to recombinant human growth hormone (rhGH), a 191-amino-acid protein. Published research has characterized recombinant human growth hormone and its structure, receptor binding, and molecular properties.
The primary molecular target is the growth hormone receptor (GHR). Research has examined how the 191-amino-acid hormone interacts with GHR, including studies of receptor-binding regions within the protein.
Research Overview Table
Chemical and Molecular Characteristics
Published studies describe human growth hormone as a single-chain protein with 191 amino acids and a four-helix bundle structure. Two intramolecular disulfide bonds stabilize its molecular architecture.
Its defined sequence and folded structure distinguish it from shorter peptide molecules. These characteristics are relevant when recombinant human growth hormone is examined for structural integrity and molecular consistency.
Certificates:
Mechanism of Action Under Investigation
HGH191AA binds to the extracellular region of the growth hormone receptor (GHR). This ligand–receptor interaction changes the arrangement of the GHR receptor complex and activates the receptor-associated tyrosine kinase JAK2. JAK2 then undergoes trans-activation and phosphorylates signaling proteins associated with the receptor.
JAK2 activation leads mainly to phosphorylation of STAT5. Phosphorylated STAT5 forms dimers and moves into the nucleus, where it regulates transcription of target genes. GHR signaling has also been linked with STAT1, STAT3, Src-family kinases, and MAPK pathways. The contribution of these pathways can differ between cellular contexts and their regulation is not fully defined.
Scientific Research Context
HGH191AA has been studied as recombinant human growth hormone across different stages of scientific research. The literature includes early laboratory research, preclinical animal studies, and a substantial body of human research. This gives the compound a relatively mature evidence base compared with compounds examined only in early laboratory or animal studies.
HGH191AA Biology and Biological Pathways
Primary Biological Function
Growth hormone is a major regulator of somatic growth and metabolic function. Its biology is closely connected with the growth hormone–IGF-1 axis, with both endocrine and tissue-specific IGF-1 contributing to its biological actions. Researchers investigate these pathways to understand how growth hormone participates in growth, protein metabolism and the regulation of carbohydrate and lipid metabolism.
Relevant Metabolic or Signalling Pathways
The growth hormone system involves several connected signaling pathways. JAK2–STAT is a major pathway, with STAT5 playing an important role in regulating IGF1 transcription. Research also links growth hormone signaling with the PI3K–AKT and MAPK pathways. These pathways are studied to better understand how growth hormone influences gene expression and cellular processes.
Tissue-Specific Biology
Growth hormone biology differs across tissues. The liver is an important site of IGF-1 production, while growth hormone-related signaling has also been studied in skeletal muscle, adipose tissue, bone, and growth-plate cartilage. These tissues provide distinct biological contexts for examining growth hormone-regulated gene expression and metabolism.
Experimental Biomarkers
Common research markers include IGF1, IGFBP-3, phosphorylated STAT5, and tissue-specific gene-expression changes. IGF1 is particularly important because its transcription is closely associated with growth hormone–STAT5 signaling. Researchers use these markers to characterize activity within the growth hormone–IGF-1 axis.
Laboratory Investigation Methods
Published research uses molecular and cellular methods to examine growth hormone signaling and related biological responses. These include gene-expression analysis, phosphorylation assays, immunoblotting, receptor studies and DNA-binding assays. Such approaches allow researchers to examine changes in receptor-associated signaling proteins and transcriptional activity within growth hormone–responsive systems.
Experimental Models Used in Published Research
Published HGH191AA-related research uses cell systems and genetically modified animal models. The main animal models include transgenic mice, growth hormone receptor knockout mice and tissue-specific GHR knockout mice.
Transgenic Mouse Models
Human growth hormone transgenic mice have been used to model altered GH expression. Their main limitation is that constitutive or ectopic GH expression does not reproduce normal human hormone regulation.
Growth Hormone Receptor Knockout Mice
GHR knockout mice model the loss of growth hormone receptor activity. The caveat is that complete receptor disruption is not the same as normal physiological variation and could have mouse genetic background specific effects.
Tissue-Specific GHR Knockout Mice
Tissue-specific GHR knockout mice have been developed for liver, muscle, adipose tissue, bone, brain, heart and other tissues. Their limitation is that targeted gene disruption may not fully reflect naturally occurring regulation of GHR activity in humans.
Cell-Based Models
In addition, cultured cells that express growth hormone receptors have been used in GH research. Their major limitation is the absence of whole organism endocrine and tissue interactions which curtails direct translation to human physiology.
HGH191AA Published Scientific Research
GH–IGF-1 Axis
The interaction of recombinant human growth hormone with the GH–IGF-1 axis has been studied extensively. Published research has evaluated circulating IGF-1 and IGFBP-3 and their changes after rhGH exposure. This work has helped to characterize the endocrine relationship of GH and IGF-1.
Protein Metabolism
Protein metabolism is another established area of investigation. Studies have examined whole-body protein turnover, leucine kinetics, protein synthesis and leucine oxidation following recombinant GH exposure. The published observations indicate that GH-related changes in protein metabolism depend on nutritional and physiological conditions.
Glucose and Lipid Metabolism
Published studies have examined the relationship between recombinant human growth hormone and glucose and lipid metabolism. Investigations have included insulin sensitivity, glucose utilization, lipolysis, fat oxidation and circulating free fatty acids. Findings have varied with treatment duration and physiological status. with some metabolic responses changing over time.
Body Composition
Changes in body composition have been extensively investigated during recombinant GH exposure. Studies have evaluated lean body mass, fat mass, regional fat distribution, and energy expenditure. Published clinical research has reported changes in these measures, although the magnitude and pattern vary according to baseline GH status, treatment duration and study design.
Bone Biology
Bone biology has been studied with measures of bone turnover and mineral status. In published reports, biochemical markers like osteocalcin, hydroxyproline and procollagen-related markers with measurements of bone mineral have been studied. These studies have generated varying observations depending on treatment duration, age, baseline GH status and skeletal condition.
Limitations of Current Research
Evidence Is Predominantly Preclinical
For HGH191AA specifically, the published literature is not organized around the commercial designation “HGH191AA.” Much of the underlying scientific evidence concerns recombinant human growth hormone more broadly. This makes it important to distinguish evidence for recombinant human growth hormone from evidence generated using a specific commercial product.
Human Clinical Evidence
Humans, a lot of research has been done on recombinant human growth hormone, but it has mostly been on specific clinical populations and treatment protocols. The results of these studies cannot be generalized to all recombinant GH preparations or research settings. Differences in participant characteristics and study conditions also impact interpretation.
Species Differences
A major limitation is the species differences in growth hormone research. Human GH preferentially interacts with species-specific growth hormone and prolactin receptors. In rodents, recombinant human GH can activate both GH and prolactin receptors complicating interpretation of animal findings.
Study Design Limitations
Published studies use varied designs, populations, treatment durations, and outcome measures. Some longer-term clinical studies have lacked untreated control groups, making it difficult to separate GH-related changes from other factors. These differences reduce direct comparability between individual studies and limit conclusions drawn from isolated findings.
Independent Replication
It is hard to evaluate independent replication on the specific designation HGH191AA, as published papers do not typically identify the material as “HGH191AA” but as recombinant human growth hormone, human GH, or somatropin. Evidence for the broader recombinant GH class should not therefore be taken as direct evidence for a particular commercial preparation automatically.
Long-Term Evidence
There are long-term studies on recombinant human growth hormone, but there are still important limitations. Systematic reviews have reported relatively few long-duration studies, limited control data and variable metabolic and cardiovascular findings. These considerations make it difficult to draw definitive conclusions about very long-term effects.
Analytical Documentation
HPLC helps assess HGH191AA purity by separating the protein from related substances and impurities. The resulting chromatographic profile provides a measurable record of sample composition.
LC-MS adds molecular mass information to the analysis. Comparison with the expected mass can support protein identity and help characterize molecular variants.
NMR may provide additional information about protein structure and conformation when the sample and experimental conditions are suitable. It can complement chromatographic and mass-based characterization.
A Certificate of Analysis (CoA) records the tests and specifications reported for a specific batch. These records give laboratory researchers traceable information about the material and support assessment of its identity and quality. Analytical documentation verifies product identity and quality, not biological performance.
Storage and Laboratory Handling
Store HGH191AA from Direct Sarms Slovenia according to the storage conditions listed on the product documentation. The supplied Certificate of Analysis specifies 2–8°C. Keep the material protected from moisture, heat and direct light, and keep the container closed when not in use.
Use HGH191AA in a clean laboratory setting to help prevent contamination. Qualified laboratory personnel should follow established handling procedures and the instructions provided with the material. HGH191AA is intended for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs Slovenia is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs Slovenia, we aim to make the research supply process simple, clear, and reliable.